# US 2021/0332137 A1 · Combination therapy for cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332137 A1
- Document ID: US20210332137A1
- Status: Published application
- Kind: A1
- Application number: 17/224,865
- Filed: 2021-04-07
- Published: 2021-10-28
- Earliest claimed: 2018-10-15
- Assignees: Five Prime Therapeutics, Inc.
- Applicants: Five Prime Therapeutics, Inc.
- Inventors: Sandeep P. INAMDAR; Helen L. COLLINS; Hong XIANG; Xiang ZHANG; Neyssa MARINA
- Web page: https://patentgrep.com/patent/US20210332137A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 to a subject in need thereof, for example, a cancer patient, in combination with a PD-1/PD-L1 antagonist, such as an anti-PD-1 antibody.

## Claims

### Claim 1

A method of treating a solid tumor in a human subject, the method comprising administering to the subject
(i) about 0.1 to about 20 mg/kg of an anti-B7-H4 antibody or antigen-binding fragment thereof that specifically binds to human B7-H4 and comprises a heavy chain variable region (VH) complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:5, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:6, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:7, a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO:8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:10; and
(ii) about 200 mg of an anti-PD-1 antibody or antigen-binding fragment thereof comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:34, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:35, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:36, a VL CDR1 comprising the amino acid sequence of SEQ ID NO:37, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:38, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:39.

### Claim 2 (depends on 1)

The method of claim 1, wherein the
anti-B7-H4 antibody or antigen binding fragment thereof is present in a pharmaceutical composition comprising
a pharmaceutically acceptable excipient, wherein at least 95% of the anti-B7-H4 antibodies or antigen-binding fragments thereof in the composition are afucosylated.

### Claim 3 (depends on 1)

The method of claim 1, wherein about 20 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein about 10 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

### Claim 5 (depends on 1)

The method of claim 1, wherein about 3 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

### Claim 6 (depends on 1)

The method of claim 1, wherein about 1 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

### Claim 7 (depends on 1)

The method of claim 1, wherein about 0.3 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

### Claim 8 (depends on 1)

The method of claim 1, wherein about 0.1 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

### Claim 9 (depends on 1)

The method of claim 1, wherein the anti-B7-H4 antibody or antigen binding fragment thereof and the anti-PD-1 antibody or antigen-binding fragment are administered concurrently.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the anti-B7-H4 antibody or antigen binding fragment thereof and the anti-PD-1 antibody or antigen-binding fragment thereof are administered sequentially.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein the anti-B7-H4 antibody or antigen binding fragment thereof is administered about once every three weeks.

### Claim 14 (depends on 1)

The method of claim 1, wherein the anti-PD-1 antibody or antigen binding fragment thereof is administered about once every three weeks.

### Claim 15 (depends on 1)

The method of claim 1, wherein the anti-B7-H4 antibody or antigen binding fragment thereof and the anti-PD-1 antibody or antigen-binding fragment thereof are each administered about once every three weeks.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The method of claim 1, wherein the anti-B7-H4 antibody or antigen binding fragment thereof comprises a VH comprising the amino acid sequence set forth in SEQ ID NO:11 and/or a VL comprising the amino acid sequence set forth in SEQ ID NO:12.

### Claim 20 (depends on 1)

The method of claim 1, wherein the anti-B7-H4 antibody or antigen binding fragment comprises a heavy chain constant region and/or a light chain constant region.

### Claim 21 (depends on 20)

The method of claim 20, wherein the heavy chain constant region is a human immunoglobulin IgG1 heavy chain constant region and/or wherein the light chain constant region is a human immunoglobulin IgGκ light chain constant region.

### Claim 22 (depends on 1)

The method of claim 1, wherein the anti-B7-H4 antibody or antigen binding fragment thereof comprises a heavy chain constant region comprising the amino acid sequence set forth in SEQ ID NO:25 and/or a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO:23.

### Claim 23 (depends on 1)

The method of claim 1, wherein the anti-B7-H4 antibody or antigen binding fragment thereof comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:21 and/or a light chain comprising the amino acid sequence set forth in SEQ ID NO:22.

### Claim 24 (depends on 1)

The method of claim 1, wherein the anti-B7-H4 antibody or antigen binding fragment thereof is a human antibody or antigen-binding fragment thereof.

### Claim 25

(canceled)

### Claim 26 (depends on 1)

The method of claim 1, wherein the anti-B7-H4 antibody or antigen binding fragment thereof is a full length antibody.

### Claim 27 (depends on 1)

The method of claim 1, wherein the anti-B7-H4 antibody or antigen binding fragment thereof is an antigen-binding fragment.

### Claim 28 (depends on 27)

The method of claim 27, wherein the antigen-binding fragment comprises a Fab, Fab′, F(ab′)2, single chain Fv (scFv), disulfide linked Fv, V-NAR domain, IgNar, intrabody, IgGACH2, minibody, F(ab′)3, tetrabody, triabody, diabody, single-domain antibody, DVD-Ig, Fcab, mAb2, (scFv)2, or scFv-Fc.

### Claim 29 (depends on 2)

The method of claim 2, wherein fucosylation of the anti-B7-H4 antibody or antigen-binding fragment thereof is undetectable in the composition.

### Claim 30 (depends on 1)

The method of claim 1, wherein the anti-PD-1 antibody or antigen binding fragment comprises a VH comprising the amino acid sequence of SEQ ID NO:32 and a VL comprising the amino acid sequence SEQ ID NO:33.

### Claim 31 (depends on 1)

The method of claim 1, wherein the anti-PD-1 antibody or antigen binding fragment is pembrolizumab.

### Claim 32

(canceled)

### Claim 33 (depends on 1)

The method of claim 1, whcrcin the method comprising administering to the subject
(i) 3, 10 or 20 mg/kg of an anti-B7-H4 antibody or antigen-binding fragment thereof that specifically binds to human B7-H4 and comprises a VH comprising the amino acid sequence set forth in SEQ ID NO:11 and a VL comprising the amino acid sequence set forth in SEQ ID NO:12, wherein the anti-B7-H4 antibody or antigen binding fragment is not detectably fucosylated; and
(ii) 200 mg of pembrolizumab;
wherein (i) and (ii) are administered intravenously as separate formulations on the same day.

### Claim 34 (depends on 33)

The method of claim 33, wherein the anti-B7-H4 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:21 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:22.

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37 (depends on 1)

The method of claim 1, wherein the solid tumor is selected from the group consisting of breast cancer, ductal carcinoma, endometrial carcinoma, ovarian cancer, urothelial cancer, non-small cell lung cancer, pancreatic cancer, thyroid cancer, kidney cancer and bladder cancer.

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41 (depends on 37)

The method of claim 37, wherein the solid tumor is triple negative breast cancer.

### Claim 42 (depends on 37)

The method of claim 37, wherein the solid tumor is a hormone-receptor (HR)-positive breast cancer.

### Claim 43 (depends on 37)

The method of claim 37, wherein the non-small cell lung cancer is squamous cell carcinoma.

### Claim 44 (depends on 1)

The method of claim 1, wherein the patient has not received prior therapy with a PD-1/PD-L1 antagonist.

### Claim 45 (depends on 1)

The method of claim 1, wherein the method further comprises monitoring the number of immune cells in the tumor and/or monitoring cytokine levels in the subject.

### Claim 46

(canceled)

### Claim 47

(canceled)

### Claim 48

(canceled)

### Claim 49 (depends on 1)

The method of claim 1, the method comprising administering to the subject
(i) about 20 mg/kg of an anti-B7-H4 antibody that specifically binds to human B7-H4 and comprises a VH comprising the amino acid sequence of SEQ ID NO:11 and a VL comprising the amino acid sequence of SEQ ID NO:12; and
(ii) about 200 mg of an anti-PD-I antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:32 and a VL comprising the amino acid sequence of SEQ ID NO:33, wherein the anti-B7-H4 antibody and the anti-PD-I antibody are administered intravenously about once every three weeks.

### Claim 50 (depends on 2)

The method of claim 2, the method comprising administering to the subject
(a) a pharmaceutical composition comprising (i) anti-B7-H4 antibodies that specifically bind to human B7-H4 and comprise a VH comprising the amino acid sequence of SEQ ID NO:11 and a VL comprising the amino acid sequence of SEQ ID NO:12 and (ii) a pharmaceutically acceptable excipient, wherein at least 95% of the anti-B7-H4 antibodies thereof in the composition are afucosylated, and wherein about 20 mg/kg of the antibodies are administered; and
(b) a pharmaceutical composition comprising an anti-PD-I antibody or antigen-binding fragment thereof comprising a VH comprising the amino acid sequence of SEQ ID NO:32 and a VL comprising the amino acid sequence of SEQ ID NO:33 and a pharmaceutically acceptable excipient, wherein about 200 mg of the antibody or antigen-binding fragment is administered,
wherein the anti-B7-H4 antibody and the anti-PD-I antibody are administered intravenously about once every three weeks.

### Claim 51 (depends on 49)

The method of claim 49, wherein the anti-B7-H4 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:21 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:22.

### Claim 52 (depends on 49)

The method of claim 49, wherein the anti-PD-1 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:30 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:31.

### Claim 53

(canceled)

### Claim 54 (depends on 51)

The method of claim 51, wherein the anti-PD-1 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:30 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:31.

### Claim 55 (depends on 50)

The method of claim 50, wherein the anti-B7-H4 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:21 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:22.

### Claim 56 (depends on 50)

The method of claim 50, wherein the anti-PD-1 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:30 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:31.

### Claim 57 (depends on 55)

The method of claim 55, wherein the anti-PD-1 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:30 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:31.
